Frontlight ResearchEarly access
TerminatedPhase 1
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 4 people enrolled
- Started
- 1 Aug 2018
- Ended
- 31 May 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Goeckerman Therapy
- Crude Coal Tar Only
- Phototherapy Only
- Record updated
- 3 August 2025
- Why it stopped
- Closing of the Goeckerman program at UCSF and loss of funding, PI left UCSF
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Male or female ≥ 18 years of age at enrollment
- Documentation of predominately moderate to severe plaque psoriasis for at least 6 months prior to enrollment
- Written informed consent obtained from subject and ability for subject to comply with the requirements of the study
- Subject is considered a candidate for phototherapy or systemic therapy
- Body Surface Area (BSA) ≥ 5%
- Physical exam within clinically acceptable limits
Who cannot take part
- Subject has drug-induced psoriasis
- Evidence of abnormality of any immune cell population from a drug-induced or genetic cause
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy
- Patient has absolute or relative contraindication to phototherapy, including photosensitizing disorders
- Known HIV positive status
- Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents
- Subject has predominantly non-plaque form of psoriasis
Where in United States
- UCSF Psoriasis and Skin Treatment CenterSan Francisco, United States
About the trial
What the trial wants to find out
This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within psoriatic skin lesions.
The 3 groups in the trial
- Goeckerman TherapyExisting treatment, for comparison
Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
- Phototherapy OnlyExisting treatment, for comparison
Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
- Crude Coal Tar OnlyExisting treatment, for comparison
Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 August 2025